Journal article

The prognostic significance of the BRAF(V600E) mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry

Penelope A McKelvie, Fiona Chan, Yong Yu, Paul Waring, Irma Gresshoff, Stephen Farrell, Richard A Williams

PATHOLOGY | ELSEVIER | Published : 2013


AIMS: BRAF mutation has been shown in a large meta-analysis to be an independent prognostic marker for papillary thyroid carcinoma (PTC) with poorer survival and higher recurrence rates. METHODS: We studied prevalence of BRAF mutation in 77 patients with PTC from an Australian cohort using competitive polymerase chain reaction (C-PCR) and immunohistochemistry (IHC) with BRAF-specific antibody, VE1. Clinicopathological parameters, recurrence and mortality were analysed according to BRAF mutation status. RESULTS: Median follow-up was 84.5 months. BRAF mutation was demonstrated in 65% of cases combining both C-PCR and IHC; in 71% (37/77) of tumours >1 cm and 52% (13/25) of microcarcinomas (45 y..

View full abstract